Therapeutically, strategies aiming to restore or enhance MHC‐II expression—such as IFN‐γ administration, CIITA overexpression, or epigenetic reactivation—show promise for augmenting T cell‐mediated tumour recognition and broadening the therapeutic scope beyond MHC‐I‐restricted approaches. This evidence concerns the gene IFNG and neoplasm.